CN114209823A - Adjuvant for pig Japanese encephalitis live vaccine composition, composition and application - Google Patents
Adjuvant for pig Japanese encephalitis live vaccine composition, composition and application Download PDFInfo
- Publication number
- CN114209823A CN114209823A CN202210075920.4A CN202210075920A CN114209823A CN 114209823 A CN114209823 A CN 114209823A CN 202210075920 A CN202210075920 A CN 202210075920A CN 114209823 A CN114209823 A CN 114209823A
- Authority
- CN
- China
- Prior art keywords
- japanese encephalitis
- virus
- adjuvant
- cell
- encephalitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000710842 Japanese encephalitis virus Species 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 229960005486 vaccine Drugs 0.000 title claims abstract description 72
- 206010014596 Encephalitis Japanese B Diseases 0.000 title claims abstract description 70
- 201000005807 Japanese encephalitis Diseases 0.000 title claims abstract description 70
- 239000002671 adjuvant Substances 0.000 title claims abstract description 45
- 241000282898 Sus scrofa Species 0.000 claims abstract description 83
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 100
- 241000700605 Viruses Species 0.000 claims description 33
- 206010014599 encephalitis Diseases 0.000 claims description 30
- 239000000725 suspension Substances 0.000 claims description 26
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 8
- 210000003501 vero cell Anatomy 0.000 claims description 6
- 238000009629 microbiological culture Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 abstract description 12
- 239000007924 injection Substances 0.000 abstract description 12
- 230000005847 immunogenicity Effects 0.000 abstract description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 4
- 239000005642 Oleic acid Substances 0.000 abstract description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract description 4
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 229920000057 Mannan Polymers 0.000 abstract 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 abstract 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 39
- 238000004114 suspension culture Methods 0.000 description 29
- 229940031551 inactivated vaccine Drugs 0.000 description 27
- 239000001963 growth medium Substances 0.000 description 25
- 239000007788 liquid Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000003833 cell viability Effects 0.000 description 14
- 238000004945 emulsification Methods 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 238000010008 shearing Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000005723 virus inoculator Substances 0.000 description 8
- 239000012752 auxiliary agent Substances 0.000 description 7
- 239000012888 bovine serum Substances 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000036528 appetite Effects 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 238000011076 safety test Methods 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003239 encephalitis vaccine Drugs 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an adjuvant for a swine Japanese encephalitis live vaccine composition, and the composition and application thereof. The adjuvant comprises: 80-96% of an aqueous solution for injection; 1-5% mannan; 0.5-5% of polyvinylpyrrolidone; 0.5-2% of hydroxymethyl cellulose; 0.5-2% of polylactic acid-glycolic acid; 0.5-2% of poloxamer; 1-4% of oleic acid. The adjuvant can be used for the pig Japanese encephalitis live vaccine composition, so that the pig Japanese encephalitis live vaccine composition has good immunogenicity and safety.
Description
Technical Field
The invention relates to the field of biological products for livestock, in particular to an adjuvant for a swine Japanese encephalitis inactivated vaccine, and a composition and application thereof.
Background
Japanese Encephalitis (JE), also known as Japanese encephalitis, is called Japanese encephalitis for short, and is a zoonosis caused by Japanese Encephalitis Virus (JEV), and China classifies pig Japanese encephalitis as a second type animal epidemic disease and pig Japanese encephalitis Virus as a third type animal pathogenic microorganism. The disease is transmitted through mosquito vector, has strict seasonality, is popular for 6-10 months, and is concentrated for 7, 8 and 9 months. Meanwhile, mosquitoes are also the long-term storage hosts of the virus, pigs are the most main proliferation hosts and infection sources, and the incidence rate of infection of children in people is high. The symptoms of animal infection are acute onset, high temperature and high fever, abortion, dead fetus and higher disease death rate. During the epidemic period, the infection rate of the pigs to the Japanese encephalitis virus can almost reach 100 percent, but the pigs are in a hidden infection state in many times and become a main source of the Japanese encephalitis infection of human beings.
Currently, there are 4 different types of JEV vaccines: inactivated mouse brain vaccine, inactivated cell culture vaccine, live attenuated cell culture vaccine and live attenuated genetic engineering vaccine. The encephalitis B vaccine for animals mainly comprises a mouse brain inactivated vaccine and a hamster kidney cell encephalitis B live vaccine. The existing pig Japanese encephalitis vaccines have certain problems, such as the disadvantages of high cost, much foreign protein, easy anaphylactic reaction and the like of vaccines prepared from rat brain, and the disadvantages of high cost, complex operation, batch difference and the like of hamster kidney cell live vaccines.
The Vero cell is derived from the kidney passage cell of the African green monkey, has the advantages of easy large-scale culture, stable cytozoology, no exogenous factor pollution and no tumorigenicity, is a human vaccine production matrix recommended by WHO, and is suitable for a cell source for large-scale vaccine production. In addition, the domestic commercial swine Japanese encephalitis vaccine adopts a traditional rotary bottle culture mode, and has the defects of easy cell pollution, high labor intensity and the like. Compared with the rotary bottle culture process, the reactor adopts serum-free culture for suspension culture, the obtained cell density, virus titer and product quality are obviously improved, the pollution of the exogenous virus without serum is avoided, and the production energy consumption is greatly reduced.
Disclosure of Invention
The invention aims to provide an adjuvant which can enhance the immunogenicity of a vaccine and is used for a live swine Japanese encephalitis vaccine composition.
The adjuvant for the swine Japanese encephalitis live vaccine composition provided by the invention comprises the following components in percentage by weight:
the adjuvant provided by the invention can be used for preparing a live vaccine composition for Japanese encephalitis of pigs.
The invention also aims to provide a pig Japanese encephalitis live vaccine composition, which comprises the adjuvant and the pig Japanese encephalitis live vaccine.
Wherein the proportion of the adjuvant to the live Japanese encephalitis vaccine is 1: 4.
The live vaccine for Japanese encephalitis of pig is prepared by mixing Japanese encephalitis antigen of pig with a freeze-drying agent and then freezing and drying in vacuum.
The freeze-drying agent is a heat-resistant freeze-drying protective agent of a swine Japanese encephalitis live vaccine in CN 103656661B. Specifically, the lyophilizate comprises, in weight percent of the lyophilizate: 1.0-1.4% of gelatin, 9-11% of sucrose, 9-11% of trehalose, 0.15-0.35% of polyvinylpyrrolidone, 0.3-0.8% of sorbitol, 0.3-0.8% of mannitol, 0.2% of PEG-60000.1, 800.01-0.02% of tween-0.02% and the pH value of 7.5.
Wherein the Japanese encephalitis virus antigen is from a culture of Japanese encephalitis virus SA 14-14-2.
The culture of the pig encephalitis B virus SA14-14-2 is obtained by culturing the pig encephalitis B virus SA14-14-2 on a full-suspension cell line Vero-zm of Vero kidney cells, wherein the Vero-zm is preserved in the China general microbiological culture Collection center (address: Beijing city rising area, North Chen West Lu No. 1 Hospital No. 3) in 26 months at 2021, and the preservation number is CGMCC No. 23098.
Wherein the porcine Japanese encephalitis virus antigen is obtained by concentrating and purifying the culture of the porcine Japanese encephalitis virus SA 14-14-2.
Wherein the Vero-zm is cultured on a V-SFM medium.
The adjuvant can be used as an immunologic adjuvant in a pig Japanese encephalitis live vaccine composition, can enhance the immunogenicity of the vaccine, and enables the pig Japanese encephalitis live vaccine composition to have good immunogenicity and safety.
The invention utilizes the concentrated and purified Japanese encephalitis virus SA14-14-2 antigen to produce the live Japanese encephalitis vaccine composition, so that the immune side reaction is obviously reduced, and the quality of the vaccine product is obviously improved.
Detailed Description
In the following description, for purposes of explanation, specific details are set forth in order to provide an understanding of the present disclosure.
The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto.
Unless otherwise specified, the percentages referred to herein are mass percentages.
Example 1 preparation of Vero Total suspension cell line
Adherent culture Vero cells adapted to the encephalitis B virus SA14-14-2 strain are used as candidate suspension domesticated cells. The adherent Vero cells are prepared into a full-suspension adaptive cell strain through two stages of domestication by a special step-by-step suspension culture medium and serum-reducing adaptation.
1. Stepwise suspension acclimation process
Digesting the adherent culture Vero cells with trypsin, and then using the cells to culture the Vero cells in a 1-2 multiplied by 10 mode6Cell/ml density, adding newborn bovine serum according to 8-10% concentration to inoculate suspension cell bottle, placing in constant temperature oscillator, 37 deg.C, 120rpm/min, 5% carbon dioxide concentration. Respectively taking the proportion of an original culture medium (DMEM) to a suspension special culture medium as 75%: 25% and 50%: 50% and 25%: 75% and 0: domesticating the four culture mediums with a proportion of 100 percent, carrying out the proportion of each culture medium for more than 3 generations of subculture cells to reach a normal suspension adaptation state (the cells reach a normal multiplication rate, the survival rate reaches more than 90 percent), and carrying out the next proportion of cell subculture until the cells are completely adapted to the special suspension culture medium for culture and can be stably subcultured.
2. Low serum suspension acclimatization process
Domesticating the suspension cells cultured in the suspension special culture medium of the newborn calf serum with the concentration of 8% -10% in a manner of gradually reducing the serum. Gradually reducing (respectively 8%, 6%, 4% and 2%) bovine serum dosage of suspension passage cells, stably passing each serum concentration cell for more than 3 generations to reach a normal suspension adaptation state of the cell (the cell reaches a normal multiplication rate, and the survival rate reaches more than 90%), carrying out next serum concentration cell passage until the cell is completely adapted to low serum suspension culture, and stably passing. The Vero whole suspension cell strain adapting to low serum is named as Vero-zm.
Vero-zm has been preserved in China general microbiological culture Collection center (address: Xilu No. 1 Hospital No. 3, North Cheng, south China, Beijing city) at 26.10.2021 with the preservation number of CGMCC No. 23098.
Adaptability of Vero-zm to different media
Four kinds of commercial Vero suspension culture special culture medium (A, B, C, D) are selected from the market for the adaptability comparison test of Vero full suspension cell strain.
Vero suspension culture special culture medium A: vero602 (Zhejiang Yishengke Biotechnology Co., Ltd., product code: Y1131);
vero suspension culture special culture medium B: V-SFM medium (Volme Biotechnology Co., Ltd., product No. M21216101-2);
special culture medium C for Vero suspension culture: CD medium (Gibco, product number: A16277-03);
special culture medium D for Vero suspension culture: CDPK15 (Jianshun organism, trade name: 10701).
Cell recovery and cell passage are carried out according to the following method, after the cells are passaged in a corresponding culture medium for 3 generations, the porcine encephalitis B SA14-14-2 virus is inoculated under the same condition, after the virus inoculation, cell staining counting (0.4 percent trypan blue staining) is carried out, after the cell survival rate is lower than 20 percent, virus liquid is harvested and sampled, and the virus content of the vaccine is determined by adopting a virus plaque test.
1. Cell resuscitation
The frozen Vero-zm was taken out from the liquid nitrogen and placed in a 37 ℃ water bath to be rapidly thawed. The thawed cells are transferred to a centrifuge tube, a fresh Vero suspension culture special culture medium (A, B, C or D) is added, the mixture is stood for 5min, then the mixture is centrifuged for 5min at 800rpm, the supernatant is discarded, and the mixture is resuspended by the fresh Vero suspension culture special culture medium. At an initial density of 0.8X 106Each cell/ml is inoculated into 50ml of suspension culture special medium which is added with 4 percent newborn bovine serum and has the total volume of 50ml in a 250ml cell shake flask, and the suspension culture special medium is placed in a constant temperature oscillator to be cultured under the conditions of 37 ℃ and 120rpm/min and the carbon dioxide concentration of 5 percent. Cells were sampled and counted daily and analyzed for cell viability and cell doubling rate. The cells are normally cultured for 48 hours to reach the normal multiplication rate of 3-6 multiplied by 106The cell viability rate of each cell/ml is more than 95 percent.
2. Cell passage
Sampling and counting after 48 hours of cell culture until the cell density reaches 3-6 multiplied by 106The cell viability rate of each cell/ml is more than 95 percent. Diluting the cells with Vero suspension culture special culture medium, and then setting the final concentration of the cells to be 0.8 multiplied by 106Each cell/ml is inoculated into 50ml of Vero suspension culture special culture medium which is added with 4 percent newborn bovine serum and has the total volume of 50ml in a 250ml cell shake flask, and the Vero suspension culture special culture medium is placed in a constant temperature oscillator to be cultured under the conditions of 37 ℃, 120rpm/min and 5 percent of carbon dioxide concentration. Cells were sampled and counted daily and analyzed for cell viability and cell doubling rate.
3. Incubation for virus inoculation
The virus inoculation amount is 0.5M.O.I, after virus inoculation, the virus adsorption process is carried out in a bioreactor under the conditions of low stirring speed of 60rpm/min, the temperature of 37 ℃, the pH value of 7.2, 50 percent of Dissolved Oxygen (DO) and the ventilation amount of 0.1-0.5 SPLM, and the adsorption time is 60 min.
4. Determination of viral content
Serial 10-fold dilution of the virus was performed to obtain 10-2、10-3、10-43 dilutions were seeded in 12-well cell plates grown with monolayers of BHK-21 cells, each dilution being provided with 3 replicate wells, 0.1 mL/well. After virus inoculation, the cells were adsorbed at 37 ℃ for 90min, covered with a cover (DMEM containing 1.5% methylcellulose and 2% calf serum), stained with crystal violet 5 days later, fixed for 30min, washed with running water, dried, and the number of plaques in each well was counted to determine the virus content (Log PFU/mL). And respectively recording parameters such as cell growth morphology, cell density and the like after 3 generations of cell culture. Specific data for the four media are detailed in table 1 below:
TABLE 1 results of four suspension media in terms of culture characteristics and toxigenic effects of Vero-zm cell lines
Remarks are as follows: cell viability was determined by counting with 0.4% trypan blue cell stain.
As can be seen from the above test results, for the four commercial culture media, the culture of Vero-zm cells in Vero suspension culture special medium B is superior to that in other 3 culture media in terms of cell density, morphology and virus production of porcine Japanese encephalitis virus SA 14-14-2. Therefore, Vero suspension culture special medium B (V-SFM medium (Volme Biotechnology Co., Ltd., product No. M21216101-2)) is preferable as a candidate medium for preparing the swine Japanese encephalitis virus antigen.
Example 2 inactivated Japanese encephalitis vaccine composition
Revivification and subculture of Vero-zm cell strain
1. Suspension seed cell resuscitation
The frozen Vero-zm cell line was taken out from the liquid nitrogen and placed in a water bath at 37 ℃ to be rapidly thawed. After thawingThe cells are transferred into a centrifuge tube, a fresh special suspension cell culture medium B is added, after standing for 5min, the centrifuge tube is centrifuged at 800rpm for 5min, the supernatant is discarded, and the suspension is resuspended by using the fresh special suspension cell culture medium. At an initial density of 0.8X 106Each cell/ml is inoculated into 50ml of suspension culture special medium which is added with 4 percent newborn bovine serum and has the total volume of 50ml in a 250ml cell shake flask, and the suspension culture special medium is placed in a constant temperature oscillator to be cultured under the conditions of 37 ℃ and 120rpm/min and the carbon dioxide concentration of 5 percent. Cells were sampled and counted daily and analyzed for cell viability and cell doubling rate. The cells are normally cultured for 48 hours to reach the normal multiplication rate of 3-6 multiplied by 106The cell viability rate of each cell/ml is more than 95 percent.
2. Cell passage
Sampling and counting after 48 hours of cell culture until the cell density reaches 3-6 multiplied by 106The cell viability rate of each cell/ml is more than 95 percent. Diluting the cells with a special culture medium for suspension culture, and then setting the final concentration of the cells to be 0.8 multiplied by 106Each cell/ml is inoculated into 50ml of suspension culture special medium which is added with 4 percent newborn bovine serum and has the total volume of 50ml in a 250ml cell shake flask, and the suspension culture special medium is placed in a constant temperature oscillator to be cultured under the conditions of 37 ℃ and 120rpm/min and 5 percent carbon dioxide concentration. Cells were sampled and counted daily and analyzed for cell viability and cell doubling rate.
Step-by-step amplification culture of Vero-zm suspension cells in bioreactor
Suspension culture of Vero-zm suspension cells in 10L bioreactor
After the cell strain is subjected to suspension culture in a shake flask for 1-3 generations, the cell strain is transferred to a 10L bioreactor, and a suspension culture medium is supplemented to ensure that the cell concentration is 0.6 multiplied by 106Adding 4% newborn calf serum into each cell/ml, culturing at 37 ℃, pH value of 7.2, Dissolved Oxygen (DO) of 50%, stirring speed of 100rpm and ventilation volume of 0.1-0.3 for 48-72 h, sampling and counting cells every day, and analyzing cell viability and cell multiplication rate. After culturing for 48-72 h, the cells reach the normal multiplication rate of 3-6 multiplied by 106cells/ml, cell viability up to more than 95%, can further expand the culture.
Continuous amplification culture of Vero-zm suspension cells in 10L-40L-100L bioreactor
Transferring Vero-zm suspension cells cultured in a 10L bioreactor to a 40L bioreactor through connection, and adding a special culture medium for suspension culture to adjust the cell density to 0.6 multiplied by 106Adding 4% of newborn bovine serum into each cell/ml, culturing at 37 ℃, pH value of 7.2, dissolved oxygen DO value of 50%, stirring speed of 100rpm and ventilation volume of 0.1-0.3 for 48-72 h, sampling and counting cells every day, and analyzing cell viability and cell multiplication rate. After culturing for 48-72 h, the cells reach the normal multiplication rate of 3-6 multiplied by 106The cell viability reaches more than 95 percent per ml, and the cells can be further expanded and cultured. With this culture process, cells were scaled up to a 100L bioreactor for culture.
Production of 100L-grade reactor of porcine Japanese encephalitis virus SA14-14-2 strain
The 100L suspension culture cell prepared by the method is subjected to cell sedimentation and liquid exchange stage, virus inoculation and incubation stage, and virus culture to harvest stage to complete the generation of the porcine Japanese encephalitis virus SA14-14-2 strain:
1. cell sedimentation liquid changing stage
And (3) standing and settling the prepared 100L of suspension culture cells in a low-temperature cold water bath at 10-20 ℃ for 4-8 h, settling most of the cells, and discharging a cell growth solution with half of the total volume through a reactor cleaning device.
2. Incubation phase for virus inoculation
After the cells are settled and changed, the porcine encephalitis B SA14-14-2 virus is inoculated, the virus inoculation amount is 0.5M.O.I, and after the virus is inoculated, the virus adsorption process is carried out in a bioreactor under the conditions of low stirring speed of 60rpm/min, the temperature of 37 ℃, the pH value of 7.2, Dissolved Oxygen (DO)50 percent and the ventilation volume of 0.1-0.5 SPLM, and the adsorption time is 60 min.
3. Culturing virus to harvest stage
After the inoculation and incubation of the virus, a suspension cell special culture medium B (pH7.8) containing 4% newborn calf serum is added to the original culture volume, and the culture is continued in a reactor at the temperature of 35 ℃, the Dissolved Oxygen (DO) of 50%, the stirring speed of 100rpm and the ventilation amount of 0.1-0.5 SPLM. Cells were observed and counted daily and cells were monitoredAdjusting the pH value by using 7.5-10% (w/v) of sodium bicarbonate according to the change of the pH value in the growth state; according to the consumption of glucose, 20-40% (w/v) of the glucose concentrated solution is used for timely supplementing the glucose in the culture solution. Culturing until the cell viability is lower than 20%, harvesting virus liquid, freezing and thawing once, sampling to detect virus titer, wherein the virus content per mL is 107.5PFU。
Concentration and purification method and process of porcine Japanese encephalitis virus SA14-14-2
1. And (3) treating a virus feed liquid sample:
collecting porcine encephalitis B SA14-14-2 virus liquid, adding protamine sulfate with final concentration of 1mg/ml, shaking up, and standing overnight at 4 ℃.
2. Centrifuging a virus feed liquid sample:
centrifuging the porcine Japanese encephalitis virus at 10000rpm for 30min by adopting a high-speed continuous centrifugation method, discarding the precipitate, collecting the virus supernatant, and storing at 4 ℃ for later use.
3. Virus feed liquid sample ultrafiltration:
3.1 system pretreatment: a300 KD hollow fiber column (Shibi pure company)/membrane-packed Rambo company) is installed in a hollow fiber/membrane-packed control equipment system (comprising a pipeline, a pump and a fiber/membrane packed), and after the assembly is finished, the whole system is flushed for 20min by sterile water for injection, and the flow rate is controlled to be 90L/min.
3.2 System integrity and Water flux detection: and (5) washing the system by sterile water for injection, and detecting the water flux of the hollow fiber column/membrane package and whether the system leaks or not at room temperature.
And (3) online sterilization and cleaning of the system: and (3) carrying out circulating sterilization treatment on the system for 30min by using a sterile 0.2mol/L NaOH solution, then cleaning the ultrafiltration system by using sterile water for injection, and washing away the residual NaOH solution until the pH value reaches 7.0.
3.3 System Balancing: the mixture was equilibrated with sterile 0.01mol/L PBS (pH7.2) for 10min at a flow rate of 60L/min. And (3) allowing the centrifuged feed liquid to pass through a 300KD hollow fiber column/membrane package system, controlling the pump speed of a liquid inlet end at 60L/min, maintaining the transmembrane pressure at a permeation end at 1.5psi, collecting liquid at a backflow end, supplementing 0.01mol/L PBS (phosphate buffer solution) solution to the original volume when 1/20 of the original volume of the feed liquid at the liquid inlet end is remained, continuing ultrafiltration, repeating the ultrafiltration for three times until the original volume reaches 1/20, and finishing the ultrafiltration process.
4. And (3) purifying by molecular sieve chromatography gel:
4.1 filling and pretreatment of chromatographic packing: and (3) installing a 4FF molecular sieve (GE company) prepacked column in place, and detecting the column effect.
4.2 treating the molecular sieve gel chromatographic column with 5-10 column volumes of sterile 0.5mol/L NaOH, then cleaning with sterile injection water to pH7.0, then balancing the chromatographic column with 5-10 column volumes of 0.01 mol/L7.2 PBS solution, wherein the conductivity is 15.45ms/cm, the pH value is stabilized at 7.2, and the ultraviolet UV280 baseline is stable.
4.5, chromatographic purification: and (3) loading the virus sample subjected to ultrafiltration concentration, setting the linear flow rate of loading to be 10ml/min, and controlling the pressure to be less than 2.0 bar. The sample loading amount is 10% of the column volume, after the sample loading is finished, 0.01mol/L PBS buffer solution is switched, the light absorption value is detected by UV280, when the light absorption value curve is in an ascending trend, the first peak appearing as the target sample is collected, the collection is stopped when the light absorption value of the light absorption value curve is reduced to the lowest position, the collected peak sample is subjected to Protein removal rate determination by using BCA Protein Assay Kit (Thermo company), and the Protein removal rate is 98.7%. And (3) continuously treating the molecular sieve gel chromatography column with 5-10 column volumes of sterile 0.5mol/L NaOH, and then washing with sterile injection water to pH7.0 to obtain the concentrated and purified porcine Japanese encephalitis virus SA14-14-2 antigen.
Preparation of pig Japanese encephalitis inactivated vaccine composition
1. Preparation of pig Japanese encephalitis inactivated antigen
Mixing beta-propiolactone and porcine Japanese encephalitis virus SA14-14-2 antigen in a weight ratio of 1: stirring and inactivating at 4000 ℃ for 24 hours, and hydrolyzing in water bath at 37 ℃ for 2 hours to obtain the inactivated antigen of the porcine Japanese encephalitis virus.
2. Preparation of animal vaccine oil adjuvant
Weighing a certain amount of emulsifier and auxiliary agent according to the following weight percentage, adding the emulsifier and auxiliary agent into weighed mineral oil for injection produced by Exxon Mobil oil company, controlling the stirring speed, carrying out physical mixing, adopting a heating and dissolving-assisting mode in the mixing process, controlling the temperature below 80 ℃, uniformly mixing to form liquid, sterilizing at 121 ℃ for 30 minutes, and cooling to the emulsification temperature to obtain the animal vaccine oil adjuvant 1-3.
The oil adjuvant 1 comprises the following components in percentage by weight:
the oil adjuvant 2 comprises the following components in percentage by weight:
the oil adjuvant 3 comprises the following components in percentage by weight:
3. preparation of pig Japanese encephalitis inactivated vaccine composition
Respectively adding the sterilized and cooled animal vaccine oil adjuvants 1-3 into an emulsification tank, stirring and mixing uniformly, controlling the stirring speed to be 1000 revolutions per minute and the emulsification temperature to be 30 ℃; slowly adding the inactivated antigen of the swine Japanese encephalitis virus with the same quantity as the animal vaccine oil adjuvant into the prepared oil adjuvant; after the addition is finished, performing pre-shearing emulsification, controlling the shearing speed to be below 3000 r/min, and controlling the process of pre-shearing emulsification to be 10 minutes; after the pre-shearing is finished, controlling the rotating speed to be 8000 rpm, and carrying out shearing emulsification, wherein the process is 15 minutes; and after emulsification is finished, labeling and subpackaging to obtain the inactivated Japanese encephalitis vaccine composition 1-3.
Safety test of pig Japanese encephalitis inactivated vaccine composition on mice
Safety experiments were performed with 12-14g ICR mice. The experiment was divided into 4 groups (group 1 of inactivated Japanese encephalitis vaccine composition, group 2 of inactivated Japanese encephalitis vaccine composition, group 3 of inactivated Japanese encephalitis vaccine composition and control group), each group consisting of 10 mice.
In the group 1 of the Japanese encephalitis inactivated vaccine composition, the group 2 of the Japanese encephalitis inactivated vaccine composition and the group 3 of the Japanese encephalitis inactivated vaccine composition, 0.03ml of the pig Japanese encephalitis inactivated vaccine composition is injected intracerebrally into each mouse, the death number of the mice within 3 days does not exceed 2, and the rest mice are continuously observed for 14 days to observe the spirit, appetite and injection parts of the mice.
In the control group, each mouse was injected intracerebrally with 0.03ml of the culture medium, and the number of deaths within 3 days was not more than 2, and the remaining mice were continuously observed for 14 days, and the spirit, appetite, and injection site of the mice were observed.
After the inactivated vaccine composition for Japanese encephalitis is injected into a mouse, the mouse is normal in clinical performance, good in mental state and normal in appetite, has no local and systemic adverse reactions, and is completely healthy and alive. The results are shown in Table 1.
TABLE 1 safety test results of inactivated vaccine composition for Japanese encephalitis of pig in ICR mouse
Immune challenge test of pig encephalitis B inactivated vaccine composition on mice
Mice were used for a mouse challenge immunization test with 12-14g ICR mice. The experiment is divided into 5 groups (pig encephalitis B inactivated vaccine composition 1 group, pig encephalitis B inactivated vaccine composition 2 group, pig encephalitis B inactivated vaccine composition 3 group, conventional oil adjuvant pig encephalitis B inactivated vaccine control group, challenge control group), and each group comprises 10 mice.
The conventional oil adjuvant porcine Japanese encephalitis inactivated vaccine control group uses a conventional oil adjuvant (alumina gel adjuvant) porcine Japanese encephalitis inactivated vaccine and is prepared according to the following method: adding the sterilized and cooled conventional oil adjuvant into an emulsification tank, uniformly stirring and mixing, controlling the stirring speed to be 1000 revolutions per minute and the emulsification temperature to be 30 ℃; slowly adding the prepared porcine Japanese encephalitis virus inactivated antigen with the same amount as that of the conventional oil adjuvant into the conventional oil adjuvant; after the addition is finished, performing pre-shearing emulsification, controlling the shearing speed to be below 3000 r/min, and controlling the process of pre-shearing emulsification to be 10 minutes; after the pre-shearing is finished, controlling the rotating speed to be 8000 rpm, and carrying out shearing emulsification, wherein the process is 15 minutes; and after emulsification is finished, labeling and subpackaging to obtain the conventional oil adjuvant porcine Japanese encephalitis inactivated vaccine.
The control group was not immunized and was used 10 days after the 2 nd vaccination of mice5LD50The Japanese encephalitis P3 is strongly toxic and acts as an abdominal cavity.
The porcine encephalitis B inactivated vaccine composition and the conventional oil adjuvant porcine encephalitis B inactivated vaccine are respectively diluted by PBS with pH 7.5 in three dilutions of 50 times, 500 times and 5000 times, 10 mice are respectively inoculated with 10-12g of each dilution through the abdominal cavity, secondary inoculation is carried out at intervals of 7 days, 0.5 ml/mouse is used for each time, and 10 mice are taken as challenge control at the same time. All mice were challenged intraperitoneally 5 days after the 2 nd inoculation 105LD50Encephalitis B P3 was virulent, 0.3ml each, and 0.04ml of virus dilution was injected intracerebrally into each mouse before abdominal challenge to disrupt the blood-brain barrier. After the virus attack, the mice in the virus attack control group are observed for 14 days (death within 3 days), no less than 80 percent of the death should occur, and half protection amount (PD) is calculated after 14 days50)。
And (3) performing immunogenicity evaluation on the inactivated swine Japanese encephalitis vaccine composition through an immune challenge test of a mouse. The result shows that the conventional oil adjuvant pig Japanese encephalitis inactivated vaccine control group PD50Is 10-2 . 030.3ml of pig Japanese encephalitis inactivated vaccine composition 1 group PD50Is 10-2.700.3ml of porcine Japanese encephalitis inactivated vaccine composition 2 group PD50Is 10-2.600.3ml of pig Japanese encephalitis inactivated vaccine composition 3 groups PD50Is 10-2.37/0.3ml。
Thus can seeThe inactivated swine Japanese encephalitis vaccine composition 1 has the best immunogenicity, and can still protect 50% of mice after being diluted by 501 times. The inactivated swine Japanese encephalitis vaccine composition 2 can still protect 50% of mice after being diluted 398 times. After the inactivated Japanese encephalitis vaccine composition 3 is diluted 234 times, 50% of mice can still be protected. The conventional oil adjuvant porcine encephalitis B inactivated vaccine group has poor immune effect and is carried out for 107After dilution by fold, 50% of the mice were protected as shown in table 2.
TABLE 2 porcine Japanese encephalitis inactivated vaccine composition half Protection Dose (PD)50) Measurement of (2)
Example 3 preparation of live porcine encephalitis B vaccine composition
1. Preparation of pig Japanese encephalitis live vaccine
Adding a freeze-drying protective agent (the heat-resistant freeze-drying protective agent for the live swine Japanese encephalitis vaccine described in CN103656661B, specifically, the heat-resistant freeze-drying protective agent for the live swine Japanese encephalitis vaccine of example 1) into the antigen SA14-14-2 of the swine Japanese encephalitis virus, and performing freeze-vacuum drying to prepare the live swine Japanese encephalitis vaccine.
2. Preparation of pig Japanese encephalitis live vaccine water adjuvant
Weighing the following auxiliary agents and polymer combinations according to a proportion, sequentially adding the auxiliary agents and the polymer combinations into the weighed water solution for injection, controlling the stirring speed, mixing, uniformly mixing into liquid by adopting a heating and dissolving assisting mode in the mixing process, controlling the temperature to be below 60 ℃, sterilizing at 121 ℃ for 30 minutes, and cooling to room temperature to obtain the swine Japanese encephalitis live vaccine aqueous adjuvant 1-3.
The swine Japanese encephalitis live vaccine water-based adjuvant 1 comprises the following components in percentage by weight:
88% of an aqueous solution for injection;
polymer combination:
auxiliary agent:
oleic acid 3%
The swine Japanese encephalitis live vaccine aqueous adjuvant 2 consists of the following components in percentage by weight:
96% of water solution for injection;
polymer combination:
auxiliary agent:
oleic acid 1%
The swine Japanese encephalitis live vaccine aqueous adjuvant 3 consists of the following components in percentage by weight:
80% of water solution for injection;
polymer combination:
auxiliary agent:
oleic acid 4%
3. Preparation of pig encephalitis B live vaccine composition
Diluting pig Japanese encephalitis live vaccine with diluent (1/15mol/L phosphate buffered saline, pH7.4) to 1 part (virus content 10)6.0PFU/ml), adding 20% by volume of the aqueous adjuvant of the live Japanese encephalitis vaccine provided by the invention 1-3, shaking up to prepare the live Japanese encephalitis vaccine composition 1-3.
4. Preparation of Japanese encephalitis live vaccine composition with conventional alumina gel adjuvant
Diluting pig Japanese encephalitis live vaccine with diluent (1/15mol/L phosphate buffered saline, pH7.4) to 1 part (virus content 10)6.0PFU/ml), adding 20% by volume of conventional commercial productsAn alumina gel adjuvant (available from Invivogen corporation) was shaken to prepare a live encephalitis b vaccine composition.
Safety test of pig Japanese encephalitis live vaccine composition on mice
Safety experiments were performed with 12-14g ICR mice. The experiment was divided into 4 groups (pig Japanese encephalitis live vaccine composition 1 group, pig Japanese encephalitis live vaccine composition 2 group, pig Japanese encephalitis live vaccine composition 3 group and control group), each group consisting of 10 mice.
In the group 1 of the pig Japanese encephalitis live vaccine composition, the group 2 of the pig Japanese encephalitis live vaccine composition and the group 3 of the pig Japanese encephalitis live vaccine composition, 0.03ml of the pig Japanese encephalitis live vaccine composition is injected intracerebrally into each mouse, the death number within 3 days does not exceed 2, and the rest mice are continuously observed for 14 days to observe the spirit, the appetite and the injection part of the mice.
In the control group, each mouse was injected intracerebrally with 0.03ml of the culture medium, and the number of deaths within 3 days was not more than 2, and the remaining mice were continuously observed for 14 days, and the spirit, appetite, and injection site of the mice were observed.
After the pig Japanese encephalitis live vaccine composition 1-3 is injected, mice are normal in clinical performance, good in mental state and normal in appetite, local and systemic adverse reactions are not generated, and the mice are all healthy and alive. The results are shown in Table 2.
TABLE 2 ICR mice for Japanese encephalitis vaccine composition safety test results
Immunization challenge test of pig Japanese encephalitis live vaccine composition on mice
Mice were used for a mouse challenge immunization test with 12-14g ICR mice. The experiment was divided into 6 groups (pig encephalitis B live vaccine composition 1 group, pig encephalitis B live vaccine composition 2 group, pig encephalitis B live vaccine composition 3 group, pig encephalitis B live vaccine group, conventional alumina gel adjuvant encephalitis B live vaccine composition group, challenge control group), each group consisting of 10 mice.
DMEM is used for diluting the pig Japanese encephalitis live vaccine composition 1-3 and the pig Japanese encephalitis live vaccine in 10-fold serial dilution. Get 10-2、10-3、10-43 dilutions, respectively subcutaneously inoculating 10-12g ICR mice each with 0.1ml, 14 days after immunization, and injecting 0.3ml of Japanese encephalitis virus virulent P3 strain (containing 500 LD) into each abdominal cavity together with 10 mice of control group with the same conditions50) The observation was continued for 14 days.
And (3) performing immunogenicity evaluation on the pig Japanese encephalitis live vaccine compositions 1-3 through an immune challenge test of a mouse. The result shows that the pig Japanese encephalitis live vaccine group PD50Is 10-3.00.3 ml; japanese encephalitis B live vaccine composition group PD with conventional alumina gel adjuvant50Is 10-3.100.3 ml; pig encephalitis B live vaccine composition 1 group PD50Is 10-3.500.3 ml; pig encephalitis B live vaccine composition 2 group ED50Is 10-3 . 430.3 ml; pig Japanese encephalitis live vaccine composition 3 groups PD50Is 10-3.29/0.3ml。
Therefore, the pig Japanese encephalitis live vaccine composition 1 has the best immunogenicity, and can still protect 50% of mice after being diluted by 3162 times; the swine Japanese encephalitis live vaccine group had the least excellent immune effect, and was diluted 1000 times, and 50% of mice were protected, as shown in Table 4.
TABLE 4 porcine Japanese encephalitis live vaccine composition half Protection Dose (PD)50) Measurement of (2)
Claims (10)
1. An adjuvant for a live swine Japanese encephalitis vaccine composition is characterized by comprising the following components in percentage by weight:
2. use of the adjuvant of claim 1 in the preparation of a live swine Japanese encephalitis vaccine composition.
3. A live swine encephalitis b vaccine composition, comprising the adjuvant of claim 1 and a live swine encephalitis b vaccine.
4. The composition according to claim 3, wherein the ratio of adjuvant to the live Japanese encephalitis vaccine is 1: 4.
5. The composition according to claim 3, wherein the live swine Japanese encephalitis vaccine is prepared by mixing a swine Japanese encephalitis antigen with a lyophilizate and then freeze-vacuum drying.
6. The composition according to claim 3, wherein the Japanese encephalitis virus antigen is from a culture of Japanese encephalitis virus SA 14-14-2.
7. The composition according to claim 6, wherein the culture of the porcine encephalitis b virus SA14-14-2 is obtained by culturing the porcine encephalitis b virus SA14-14-2 on Vero-zm, a whole suspension cell line of Vero-cells, which has been deposited at 26 months at 2021 with the China general microbiological culture Collection center (CGMCC) with the accession number of CGMCC No. 23098.
8. The composition according to claim 7, characterized in that the pig Japanese encephalitis virus antigen is obtained by concentration and purification of the culture of the pig Japanese encephalitis virus SA 14-14-2.
9. The composition of claim 7, wherein the Vero-zm is cultured on V-SFM medium.
10. The composition of claim 5, wherein the lyophilizate comprises, in weight percent of the lyophilizate: 1.0-1.4% of gelatin, 9-11% of sucrose, 9-11% of trehalose, 0.15-0.35% of polyvinylpyrrolidone, 0.3-0.8% of sorbitol, 0.3-0.8% of mannitol, 0.2% of PEG-60000.1, 800.01-0.02% of tween-0.02% and the pH value of 7.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210075920.4A CN114209823A (en) | 2022-01-23 | 2022-01-23 | Adjuvant for pig Japanese encephalitis live vaccine composition, composition and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210075920.4A CN114209823A (en) | 2022-01-23 | 2022-01-23 | Adjuvant for pig Japanese encephalitis live vaccine composition, composition and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114209823A true CN114209823A (en) | 2022-03-22 |
Family
ID=80708633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210075920.4A Pending CN114209823A (en) | 2022-01-23 | 2022-01-23 | Adjuvant for pig Japanese encephalitis live vaccine composition, composition and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114209823A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102166356A (en) * | 2011-04-12 | 2011-08-31 | 西安交通大学 | Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same |
| CN103656661A (en) * | 2013-11-21 | 2014-03-26 | 中牧实业股份有限公司 | Porcine Japanese encephalitis live vaccine heat-resistant lyophilized protective agent as well as preparation method and application thereof |
| CN105688202A (en) * | 2016-03-03 | 2016-06-22 | 四川农业大学 | Japanese encephalitis (JE) vaccine composition and preparing method thereof |
| CN105688207A (en) * | 2016-03-11 | 2016-06-22 | 中牧实业股份有限公司 | Compound adjuvant for animal vaccine and application of compound adjuvant |
| CN105816873A (en) * | 2016-03-11 | 2016-08-03 | 中牧实业股份有限公司 | Polymer combined adjuvant of animal vaccine and applications thereof |
| CN106754762A (en) * | 2016-11-22 | 2017-05-31 | 中牧实业股份有限公司 | A kind of antigen of encephalitis B live vaccine and preparation method and application |
| CN107050447A (en) * | 2016-11-14 | 2017-08-18 | 陕西诺威利华生物科技有限公司 | Porcine epidemic diarrhea virus inactivated vaccine and preparation method thereof |
| US20210180027A1 (en) * | 2017-11-09 | 2021-06-17 | Jianshun Biosciences Co., Ltd. | Method for Acclimating and Suspending Vero and Second Order Production Process for Virus |
-
2022
- 2022-01-23 CN CN202210075920.4A patent/CN114209823A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102166356A (en) * | 2011-04-12 | 2011-08-31 | 西安交通大学 | Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same |
| CN103656661A (en) * | 2013-11-21 | 2014-03-26 | 中牧实业股份有限公司 | Porcine Japanese encephalitis live vaccine heat-resistant lyophilized protective agent as well as preparation method and application thereof |
| CN105688202A (en) * | 2016-03-03 | 2016-06-22 | 四川农业大学 | Japanese encephalitis (JE) vaccine composition and preparing method thereof |
| CN105688207A (en) * | 2016-03-11 | 2016-06-22 | 中牧实业股份有限公司 | Compound adjuvant for animal vaccine and application of compound adjuvant |
| CN105816873A (en) * | 2016-03-11 | 2016-08-03 | 中牧实业股份有限公司 | Polymer combined adjuvant of animal vaccine and applications thereof |
| CN107050447A (en) * | 2016-11-14 | 2017-08-18 | 陕西诺威利华生物科技有限公司 | Porcine epidemic diarrhea virus inactivated vaccine and preparation method thereof |
| CN106754762A (en) * | 2016-11-22 | 2017-05-31 | 中牧实业股份有限公司 | A kind of antigen of encephalitis B live vaccine and preparation method and application |
| US20210180027A1 (en) * | 2017-11-09 | 2021-06-17 | Jianshun Biosciences Co., Ltd. | Method for Acclimating and Suspending Vero and Second Order Production Process for Virus |
Non-Patent Citations (4)
| Title |
|---|
| CHUN FANG SHEN ET AL.: "Development of suspension adapted Vero cell culture process technology for production of viral vaccines", 《VACCINE》, vol. 37, no. 47, 6 July 2019 (2019-07-06), pages 6996 - 7002, XP085880229, DOI: 10.1016/j.vaccine.2019.07.003 * |
| OWEN PROUDFOOT ET AL.: "Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung", 《BMC INFECT DIS》, vol. 15, 26 February 2015 (2015-02-26), pages 1 - 9 * |
| 姜威 等: "多糖佐剂在疫苗中的应用", 《中国新药杂志》, vol. 21, no. 13, 15 July 2012 (2012-07-15), pages 1470 - 1478 * |
| 韩伟 等: "猪乙型脑炎病毒在Vero细胞上的繁殖特性及其灭活疫苗的免疫原性研究", 《中国畜牧兽医》, vol. 45, no. 12, 18 December 2018 (2018-12-18), pages 3572 - 3578 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI602574B (en) | Pcv/mycoplasma hyopneumoniae combination vaccine | |
| CN107267466B (en) | Method for large-scale production of porcine pseudorabies inactivated vaccine | |
| TW201345550A (en) | Mycoplasma hyopneumoniae vaccine | |
| CN105579060A (en) | PCV2B divergent vaccine composition and methods of use | |
| CN102228686B (en) | Process for preparing veterinary rabies inactivated and freeze-dried vaccine through suspension culture cell | |
| CN114774372B (en) | Coxsackie virus A10 type strain and vaccine and application thereof | |
| EP2075005B1 (en) | Ipv-dpt vaccine | |
| CN109306360A (en) | A kind of method and its application using baculovirus expression foreign protein | |
| CN114317414B (en) | Whole suspension cell strain of African green monkey kidney cells and application thereof | |
| CN114209823A (en) | Adjuvant for pig Japanese encephalitis live vaccine composition, composition and application | |
| CN105087501A (en) | Porcine circovirus type 2 strain, inactivated vaccine prepared from porcine circovirus type 2 strain and application of porcine circovirus type 2 strain | |
| CN114209822A (en) | Adjuvant for pig Japanese encephalitis inactivated vaccine composition, composition and application thereof | |
| CN105543120B (en) | Haemophilus parasuis pentavalent inactivated vaccine | |
| CN105754905A (en) | Pseudomonas aeruginosa of minks and application of pseudomonas aeruginosa | |
| CN111073863B (en) | Porcine epidemic diarrhea and porcine delta coronavirus bivalent attenuated vaccine and preparation method thereof | |
| CN109280648B (en) | Method for preparing mink parvoviral enteritis antigen-protein complex, antigen-protein complex and application of antigen-protein complex | |
| CN103421729B (en) | Gene recombined swine cholera salmonella choleraesuis vaccine for blue-ear disease and application thereof | |
| CN107198771B (en) | Method for producing porcine pseudorabies gE gene deletion virus vaccine by microcarrier suspension culture cells | |
| RU2325437C1 (en) | Attenuated strain of goatpox virus | |
| WO2024032360A1 (en) | Lumpy skin disease virus strain, inactivated vaccine prepared from same, and method for preparing vaccine | |
| CN114805554B (en) | Refined egg yolk antibody injection for resisting streptococcus suis and haemophilus parasuis and preparation method thereof | |
| CN1265841C (en) | Swing breeding and respiratory syndrome suicide DNA vaccine and use | |
| CN109280649B (en) | Method for preparing mink canine distemper antigen-protein complex, antigen-protein complex and application of antigen-protein complex | |
| CN103436497B (en) | A kind of pig parvoviral strain | |
| CN105727274A (en) | Inactivated vaccine for mink pseudomonas aeruginosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |